CDT Quote, Financials, Valuation and Earnings

LENZ Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat LENZ Therapeutics's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 66.24%. Given that LENZ Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe LENZ Therapeutics is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$6.5M is higher than LENZ Therapeutics's net income of -$12.7M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Oruka Therapeutics's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Oruka Therapeutics has an analysts' consensus of $39.86 which suggests that it could grow by 218.86%. Given that Oruka Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Oruka Therapeutics is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.664, suggesting its less volatile than the S&P 500 by 33.629%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$6.5M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PetMed Express has a net margin of -- compared to Conduit Pharmaceuticals's net margin of -1.33%. Conduit Pharmaceuticals's return on equity of -- beat PetMed Express's return on equity of 0.37%.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand PetMed Express has an analysts' consensus of $3.75 which suggests that it could fall by -10.5%. Given that PetMed Express has higher upside potential than Conduit Pharmaceuticals, analysts believe PetMed Express is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PetMed Express has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.429%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetMed Express offers a yield of 0% to investors and pays a quarterly dividend of $0.30 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. PetMed Express pays out -166.63% of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than PetMed Express quarterly revenues of $53M. Conduit Pharmaceuticals's net income of -$6.5M is lower than PetMed Express's net income of -$707K. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while PetMed Express's PE ratio is 419.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus 0.35x for PetMed Express. Usually stocks with elevated PS ratios are considered overvalued.